Provided by Tiger Trade Technology Pte. Ltd.

Werewolf Therapeutics, Inc.

0.6600
-0.0102-1.52%
Volume:556.42K
Turnover:363.75K
Market Cap:32.04M
PE:-0.41
High:0.6776
Open:0.6600
Low:0.6302
Close:0.6702
52wk High:2.38
52wk Low:0.5301
Shares:48.54M
Float Shares:35.00M
Volume Ratio:1.90
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6177
EPS(LYR):-1.6273
ROE:-122.43%
ROA:-40.75%
PB:1.08
PE(LYR):-0.41

Loading ...

Werewolf Therapeutics Q3 EPS $(0.36) Beats $(0.39) Estimate

Benzinga
·
Nov 04, 2025

Werewolf Therapeutics Reports Q3 2025 Results and Plans Key Trial Updates

Reuters
·
Nov 04, 2025

MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Common Shares

Reuters
·
Nov 04, 2025

10% Owner Ansbert Gadicke Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Nov 04, 2025

Werewolf Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Oct 30, 2025

MPM BioVentures 2014, L.P. Reports Disposal of Werewolf Therapeutics Inc. Common Shares

Reuters
·
Oct 30, 2025

Werewolf Therapeutics’ Promising Study on WTX-124 in Cancer Treatment

TIPRANKS
·
Oct 28, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, First Majestic, Best Buy

Reuters
·
Oct 09, 2025

Werewolf Therapeutics Shares up 4% After Co Receives FDA's 'Fast Track' Tag for Cancer Therapy

THOMSON REUTERS
·
Oct 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Ford Motor, CVS Health, Phillips 66

Reuters
·
Oct 08, 2025

Werewolf Therapeutics Receives FDA Fast Track Designation for WTX124 in Advanced Melanoma

Reuters
·
Oct 08, 2025

Werewolf Therapeutics Receives Fast Track Designation From the U.S. FDA for Wtx-124, an Investigational Therapy for the Treatment of Cancer

THOMSON REUTERS
·
Oct 08, 2025

Werewolf Therapeutics Inc: Anticipate Sharing Preliminary Data From Ongoing Wtx-124 Phase 1/1B Clinical Trial in Q4

THOMSON REUTERS
·
Oct 08, 2025

Werewolf Therapeutics Faces Nasdaq Compliance Challenge

TIPRANKS
·
Oct 07, 2025

Werewolf Therapeutics Faces Nasdaq Noncompliance After Audit Committee Member’s Passing; Plans to Regain Compliance

Reuters
·
Oct 07, 2025

Werewolf Therapeutics Announces New Clinical Data and Drug Development Advances at SITC 2025 Annual Meeting

Reuters
·
Oct 03, 2025

3 Promising Penny Stocks With Market Caps Under $700M

Simply Wall St.
·
Sep 26, 2025

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire
·
Sep 02, 2025

Werewolf Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Aug 26, 2025